['familial partial lipodystrophy']
['volanesorsen', 'placebo']

        Inclusion Criteria:

          -  Must give written informed consent to participate in the study (signed and dated) and
             any authorizations required by law

          -  Clinical diagnosis of FPL plus diagnosis of type 2 diabetes mellitus,
             hypertriglyceridemia, and fatty liver

               -  Diagnosis of FPL is based on deficiency of subcutaneous body fat in a partial
                  fashion assessed by physical examination and low skinfold thickness in anterior
                  thigh by caliper measurement: men (≤ 10 mm) and women (≤ 22 mm), and at least 1
                  of the following:

                    1. Genetic diagnosis of FPL OR

                    2. Family history of FPL or of similar abnormal fat distribution plus 1 Minor
                       Criteria OR

                    3. In the absence of FPL-associated genetic variant or family history, 2 Minor
                       Criteria and BMI< 35 kg/m2

               -  Diabetes not well controlled on antidiabetic therapy with HbA1c ≥ 7% to ≤ 12% at
                  Screening

               -  Hypertriglyceridemia with Fasting TG levels ≥ 500 mg/dL (≥ 5.7 mmol/L) at
                  Screening and Qualification visit, or Fasting TG levels ≥ 200 (≥ 2.26 mmol/L) at
                  both Screening and Qualification Visits for patients who meet the genetic or
                  family history criteria

               -  Presence of hepatosteatosis (fatty liver), as evidenced by a Screening MRI
                  indicating a hepatic fat fraction (HFF) ≥ 6.4%.

        Exclusion Criteria:

          -  A diagnosis of generalized lipodystrophy

          -  A diagnosis of acquired partial lipodystrophy

          -  Acute pancreatitis within 4 weeks of Screening

          -  History within 6 months of Screening of acute or unstable cardiac condition

          -  LDL-C > 130 mg/dL on maximal tolerated statin therapy

          -  Platelet count < lower limit of normal (LLN)

          -  Treatment with metreleptin within the last 3 months prior to Screening
      